The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity
Abstract
To study both the pathophysiologic and the prognostic value of ADAMTS13 in thrombotic microangiopathies (TMAs), we enrolled a cohort of 35 adult patients combining a first acute episode of TMA, an undetectable (below 5%) ADAMTS13 activity in plasma, and no clinical background such as sepsis, cancer, HIV, and transplantation. All patients were treated by steroids and plasma exchange, and an 18-month follow-up was scheduled. Remission was obtained in 32 patients (91.4%), and 3 patients died (8.6%) after the first attack. At presentation, ADAMTS13 antigen was decreased in 32 patients (91.4%), an ADAMTS13 inhibitor was detectable in 31 patients (89%), and an anti-ADAMTS13 IgG/IgM/IgA was present in 33 patients (94%). The 3 decedent patients were characterized by the association of several anti-ADAMTS13 Ig isotypes, including very high IgA titers, while mortality was independent of the ADAMTS13 inhibitor titer. In survivors, ADAMTS13 activity in remission increased to levels above 15% in 19 patients (59%) but remained undetectable in 13 patients (41%). Six patients relapsed either once or twice (19%) during the follow-up. High levels of inhibitory anti-ADAMTS13 IgG at presentation were associated with the persistence of an undetectable ADAMTS13 activity in remission, the latter being predictive for relapses within an 18-month delay.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura
Tsai, H.-M., & Lian, E. C.-Y. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392203 · Cited by 1,760
Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura
Levy, G. G., Nichols, W. C., Lian, E. C., Foroud, T., McClintick, J. N., McGee, B. M., Yang, A. Y., Siemieniak, D. R., Stark, K. R., Gruppo, R., et al. (2001) · Nature · doi:10.1038/35097008 · Cited by 1,749
Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P. A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392202 · Cited by 1,657
Moake, J. L. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020528 · Cited by 1,221
Vesely, S. K., George, J. N., Lämmle, B., Studt, J.-D., Alberio, L., El-Harake, M. A., & Raskob, G. E. (2003) · Blood · doi:10.1182/blood-2003-01-0193 · Cited by 676
Thrombotic Thrombocytopenic Purpura
(2006) · New England Journal of Medicine · doi:10.1056/nejmc061483 · Cited by 573
Thrombotic Thrombocytopenic Purpura
George, J. N. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp053024 · Cited by 485
Galla, J. H. (1995) · Kidney International · doi:10.1038/ki.1995.50 · Cited by 301
Proteolytic inactivation of ADAMTS13 by thrombin and plasmin
Crawley, J. T. B., Lam, J. K., Rance, J. B., Mollica, L. R., O'Donnell, J. S., & Lane, D. A. (2005) · Blood · doi:10.1182/blood-2004-03-1101 · Cited by 243
Myeloma bone disease: pathophysiology and management
Terpos, E., & Dimopoulos, M.-A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi235 · Cited by 235
Cited by
Scully, M., Hunt, B. J., Benjamin, S., Liesner, R., Rose, P., Peyvandi, F., Cheung, B., Machin, S. J., & on behalf of British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09167.x · Cited by 863
Thrombotic thrombocytopenic purpura
Joly, B. S., Coppo, P., & Veyradier, A. (2017) · Blood · doi:10.1182/blood-2016-10-709857 · Cited by 716
Self-citationVon Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura
Sadler, J. E. (2008) · Blood · doi:10.1182/blood-2008-02-078170 · Cited by 574
Survival and relapse in patients with thrombotic thrombocytopenic purpura
Hovinga, J. A. K., Vesely, S. K., Terrell, D. R., Lämmle, B., & George, J. N. (2010) · Blood · doi:10.1182/blood-2009-09-243790 · Cited by 574
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
Self-citation
Metadata
- Authors
- Ferrari, S., Scheiflinger, F., Rieger, M., Mudde, G., Wolf, M., Coppo, P., Girma, J.-P., Azoulay, E., Brun-Buisson, C., Fakhouri, F., Mira, J.-P., Oksenhendler, E., Poullin, P., Rondeau, E., Schleinitz, N., Schlemmer, B., Teboul, J.-L., Vanhille, P., Vernant, J.-P., Meyer, D., Veyradier, A., & for the French and Clinical Biological Network on Adult Thrombotic Microangiopathies
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-12-12
- Volume
- 109
- Issue
- 7
- Pages
- 2815-2822
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1968875627
- Cited by
- 295
- References
- 20
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. https://app.cochat.ai/papers/10.1182/blood-2006-02-006064
- The paper
- Ferrari, S., Scheiflinger, F., Rieger, M., Mudde, G., Wolf, M., Coppo, P., Girma, J.-P., Azoulay, E., Brun-Buisson, C., Fakhouri, F., Mira, J.-P., Oksenhendler, E., Poullin, P., Rondeau, E., Schleinitz, N., Schlemmer, B., Teboul, J.-L., Vanhille, P., Vernant, J.-P., . . . for the French and Clinical Biological Network on Adult Thrombotic Microangiopathies. (2007). Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood. https://doi.org/10.1182/blood-2006-02-006064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.